These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38818978)

  • 1. Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials.
    Martino EA; Palmieri S; Galli M; Derudas D; Mina R; Della Pepa R; Zambello R; Vigna E; Bruzzese A; Mangiacavalli S; Zamagni E; Califano C; Musso M; Conticello C; Cerchione C; Mele G; Di Renzo N; Offidani M; Tarantini G; Casaluci GM; Rago A; Ria R; Uccello G; Barilà G; Palumbo G; Pettine L; Vincelli ID; Brunori M; Accardi F; Amico V; Amendola A; Fontana R; Bongarzoni V; Rossini B; Cotzia E; Gozzetti A; Rizzi R; Sgherza N; Reddiconto G; Maroccia A; Franceschini L; Bertuglia G; Nappi D; Barbieri E; Gamberi B; Petrucci MT; Di Raimondo F; Neri A; Morabito F; Musto P; Gentile M
    Hematol Oncol; 2024 Jul; 42(4):e3290. PubMed ID: 38818978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials.
    Bruzzese A; Derudas D; Galli M; Martino EA; Rocco S; Conticello C; Califano C; Giuliani N; Mangiacavalli S; Farina G; Lombardo A; Brunori M; Rossi E; Antonioli E; Ria R; Zambello R; Di Renzo N; Mele G; Marcacci G; Pietrantuono G; Palumbo G; Cascavilla N; Cerchione C; Belotti A; Criscuolo C; Uccello G; Curci P; Vigna E; Mendicino F; Iaccino E; Mimmi S; Botta C; Vincelli D; Sgherza N; Bonalumi A; Cupelli L; Stocchi R; Martino M; Ballanti S; Gangemi D; Gagliardi A; Gamberi B; Pompa A; Tripepi G; Frigeri F; Consoli U; Bringhen S; Zamagni E; Patriarca F; De Stefano V; Di Raimondo F; Palmieri S; Petrucci MT; Offidani M; Musto P; Boccadoro M; Cavo M; Neri A; Morabito F; Gentile M
    Hematol Oncol; 2022 Oct; 40(4):704-715. PubMed ID: 35608183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial.
    Dimopoulos MA; Lonial S; Betts KA; Chen C; Zichlin ML; Brun A; Signorovitch JE; Makenbaeva D; Mekan S; Sy O; Weisel K; Richardson PG
    Cancer; 2018 Oct; 124(20):4032-4043. PubMed ID: 30204239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials.
    Gentile M; Vigna E; Palmieri S; Galli M; Derudas D; Mina R; Della Pepa R; Zambello R; Martino EA; Bruzzese A; Mangiacavalli S; Zamagni E; Califano C; Musso M; Conticello C; Cerchione C; Mele G; Di Renzo N; Offidani M; Tarantini G; Casaluci GM; Rago A; Ria R; Uccello G; Barilà G; Palumbo G; Pompa A; Vincelli D; Brunori M; Accardi F; Amico V; Amendola A; Fontana R; Bongarzoni V; Rossini B; Cotzia E; Gozzetti A; Rizzi R; Sgherza N; Ferretti E; Bertuglia G; Nappi D; Petrucci MT; Di Raimondo F; Neri A; Morabito F; Musto P
    Haematologica; 2024 Jan; 109(1):245-255. PubMed ID: 37439329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
    Dimopoulos MA; Terpos E; Boccadoro M; Delimpasi S; Beksac M; Katodritou E; Moreau P; Baldini L; Symeonidis A; Bila J; Oriol A; Mateos MV; Einsele H; Orfanidis I; Ahmadi T; Ukropec J; Kampfenkel T; Schecter JM; Qiu Y; Amin H; Vermeulen J; Carson R; Sonneveld P;
    Lancet Oncol; 2021 Jun; 22(6):801-812. PubMed ID: 34087126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
    Dimopoulos MA; Dytfeld D; Grosicki S; Moreau P; Takezako N; Hori M; Leleu X; LeBlanc R; Suzuki K; Raab MS; Richardson PG; Popa McKiver M; Jou YM; Shelat SG; Robbins M; Rafferty B; San-Miguel J
    N Engl J Med; 2018 Nov; 379(19):1811-1822. PubMed ID: 30403938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetic and exposure-response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma.
    Ide T; Osawa M; Sanghavi K; Vezina HE
    Cancer Chemother Pharmacol; 2022 Jan; 89(1):129-140. PubMed ID: 34825942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
    Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
    Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world: The retrospective IMAGE study.
    Decaux O; Fontan J; Perrot A; Karlin L; Touzeau C; Schulmann S; Manier S; Belhadj K; Trebouet A; Zunic P; Schiano De Colella JM; Castel B; Van De Wyngaert Z; Pica GM; Tiab M; Kuhnowski F; Bouketouche M; Rigaudeau S; Benramdane R; Tekle C; Lafore R; Gaucher M; Corre J; Leleu X
    Eur J Haematol; 2024 Sep; 113(3):290-297. PubMed ID: 38712850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
    Miguel JS; Weisel K; Moreau P; Lacy M; Song K; Delforge M; Karlin L; Goldschmidt H; Banos A; Oriol A; Alegre A; Chen C; Cavo M; Garderet L; Ivanova V; Martinez-Lopez J; Belch A; Palumbo A; Schey S; Sonneveld P; Yu X; Sternas L; Jacques C; Zaki M; Dimopoulos M
    Lancet Oncol; 2013 Oct; 14(11):1055-1066. PubMed ID: 24007748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers.
    Hose D; Schreder M; Hefner J; Bittrich M; Danhof S; Strifler S; Krauth MT; Schoder R; Gisslinger B; Einsele H; Gisslinger H; Knop S
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):205-212. PubMed ID: 32683487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
    Mateos MV; Blacklock H; Schjesvold F; Oriol A; Simpson D; George A; Goldschmidt H; Larocca A; Chanan-Khan A; Sherbenou D; Avivi I; Benyamini N; Iida S; Matsumoto M; Suzuki K; Ribrag V; Usmani SZ; Jagannath S; Ocio EM; Rodriguez-Otero P; San Miguel J; Kher U; Farooqui M; Liao J; Marinello P; Lonial S;
    Lancet Haematol; 2019 Sep; 6(9):e459-e469. PubMed ID: 31327687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis.
    Bringhen S; Pour L; Vorobyev V; Vural F; Warzocha K; Benboubker L; Koh Y; Maisnar V; Karlin L; Pavic M; Campana F; Le Guennec S; Menas F; van de Velde H; Richardson PG
    Leuk Res; 2021 May; 104():106576. PubMed ID: 33839618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isatuximab-pomalidomide-dexamethasone
    Richardson PG; Perrot A; Miguel JS; Beksac M; Spicka I; Leleu X; Schjesvold F; Moreau P; Dimopoulos MA; Huang SY; Minarik J; Cavo M; Prince HM; Macé S; Zhang R; Dubin F; Morisse MC; Anderson KC
    Haematologica; 2024 Jul; 109(7):2239-2249. PubMed ID: 38299578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
    Mark TM; Forsberg PA; Rossi AC; Pearse RN; Pekle KA; Perry A; Boyer A; Tegnestam L; Jayabalan D; Coleman M; Niesvizky R
    Blood Adv; 2019 Feb; 3(4):603-611. PubMed ID: 30792190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
    Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
    Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.
    Afifi S; Michael A; Lesokhin A
    Ann Pharmacother; 2016 Jul; 50(7):555-68. PubMed ID: 27083916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nivolumab, Pomalidomide, and Elotuzumab Combination Regimens for Treatment of Relapsed and Refractory Multiple Myeloma: Results from the Phase 3 CheckMate 602 Study.
    Oriol A; Hájek R; Spicka I; Sandhu I; Cohen YC; Gatt ME; Mariz J; Cavo M; Berdeja J; Jin K; Bar M; Das P; Motte-Mohs R; Wang Y; Perumal D; Costa LJ
    Clin Lymphoma Myeloma Leuk; 2024 Oct; 24(10):703-714. PubMed ID: 38849283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab-naïve relapsed multiple myeloma.
    Dima D; Mansour R; Davis JA; Minchak M; Goel U; Atallah R; Logan E; Tabak C; Rashid A; Ahmed N; Abdallah AO; Hashmi H
    Eur J Haematol; 2024 Jun; 112(6):975-983. PubMed ID: 38382632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.
    Hou J; Jin J; Xu Y; Wu D; Ke X; Zhou D; Lu J; Du X; Chen X; Li J; Liu J; Gupta N; Hanley MJ; Li H; Hua Z; Wang B; Zhang X; Wang H; van de Velde H; Richardson PG; Moreau P
    J Hematol Oncol; 2017 Jul; 10(1):137. PubMed ID: 28683766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.